RTT

Over-The-Counter Drugs Exhibit a Spike in Demand Worldwide as Hospitals Become Overstretched - ResearchAndMarkets.com

Monday, April 6, 2020 - 10:00pm

DUBLIN, April 6, 2020 /PRNewswire/ -- ResearchAndMarkets.com identifies Over-the-counter Drugs as one of the key industries seeing increased demand due to the coronavirus pandemic.

Key Points: 
  • DUBLIN, April 6, 2020 /PRNewswire/ -- ResearchAndMarkets.com identifies Over-the-counter Drugs as one of the key industries seeing increased demand due to the coronavirus pandemic.
  • With hospitals overstretched by the crisis and mild cases of COVID-19 treatable with paracetamol and other common drugs, pharmacies and other retailers will have to keep well stocked.
  • Also, other health problems don't stop for a pandemic, and people have all the same diseases they would ordinarily have, with the same demand for pharmaceuticals.
  • Latest available reports on this sector include:

The Global Pulmonary Arterial Hypertension Market is expected to grow from USD 7,196.48 Million in 2019 to USD 9,925.12 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 5.50%

Monday, April 6, 2020 - 9:30pm

The Prostacyclin & Prostacyclin Analog commanded the largest size in the Pulmonary Arterial Hypertension Market in 2019, followed by the Calcium Channel Blocker.

Key Points: 
  • The Prostacyclin & Prostacyclin Analog commanded the largest size in the Pulmonary Arterial Hypertension Market in 2019, followed by the Calcium Channel Blocker.
  • On the basis of Distribution, the Pulmonary Arterial Hypertension Market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.
  • The Hospital Pharmacy commanded the largest size in the Pulmonary Arterial Hypertension Market in 2019, followed by the Retail Pharmacy.
  • On the basis of Geography, the Pulmonary Arterial Hypertension Market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa.

Huntsman Producing Hand Sanitizer in the U.S. to Aid in COVID-19 Response

Monday, April 6, 2020 - 4:45pm

The move follows the company's announcement on March 23that it would begin making hydro alcoholic solution to produce hand sanitizer in Switzerland.

Key Points: 
  • The move follows the company's announcement on March 23that it would begin making hydro alcoholic solution to produce hand sanitizer in Switzerland.
  • Huntsman will donate free of charge the first 5-ton shipment of hand sanitizer to Huntsman Cancer Institute (HCI) and the associated medical facilities at the University of Utah to help protect health care workers treating COVID-19 patients.
  • After the U.S. Food and Drug Administration (FDA) recently published temporary guidelines permitting Huntsman to produce hand sanitizer at the site, the company quickly mobilized to develop a manufacturing process to produce the sanitizer.
  • My deepest appreciation to Huntsman Corporation for its innovation and swift response in meeting this need."

Pulmonary Fibrosis Foundation Statement on COVID-19

Monday, April 6, 2020 - 4:20pm

CHICAGO, April 6, 2020 /PRNewswire/ -- Several media reports of cases of pulmonary fibrosis resulting from COVID-19 disease have raised important questions in the pulmonary fibrosis community.

Key Points: 
  • CHICAGO, April 6, 2020 /PRNewswire/ -- Several media reports of cases of pulmonary fibrosis resulting from COVID-19 disease have raised important questions in the pulmonary fibrosis community.
  • Post-ARDS fibrosis and pulmonary fibrosis that occurs in interstitial lung disease (ILD) have distinct differences.
  • However, at this time, there is no known cure for pulmonary fibrosis regardless of its cause.
  • The Pulmonary Fibrosis Foundation (PFF) mobilizes people and resources to provide access to high quality care and leads research for a cure so people with pulmonary fibrosis will live longer, healthier lives.

InventHelp Presents Early Warning System for Heat-Related Illnesses (MOA-232)

Monday, April 6, 2020 - 4:45pm

"I thought that this idea could help to reduce the incidence of heat stroke."

Key Points: 
  • "I thought that this idea could help to reduce the incidence of heat stroke."
  • He developed the patent-pending POP to serve as a detection system for hyperthermia (heat stroke).
  • The device helps the individual to recognize signs and symptoms of heat-related illness.
  • 18-MOA-232, InventHelp, 217 Ninth Street, Pittsburgh, PA 15222, or call (412) 288-1300 ext.

MedinCell Has Launched a COVID-19 Research Initiative Based on Its Experience to Formulate Long-Acting Injectable Ivermectin

Monday, April 6, 2020 - 6:41pm

Ivermectin has a long track record of use as a safe and effective drug to treat several parasitic diseases.

Key Points: 
  • Ivermectin has a long track record of use as a safe and effective drug to treat several parasitic diseases.
  • MedinCell has launched a few weeks ago a research initiative on a long-acting injectable formulation of Ivermectin and believes it could have a role to play in Covid-19 management.
  • In case of positive results, a BEPO technology based long-acting injectable Ivermectin offers a rapidly deployable and affordable solution for a global pandemic.
  • Based in Montpellier, MedinCell currently employs more than 130 people representing over 25 different nationalities.

Over-The-Counter Drugs Experience Surge in Demand due to Spread of COVID-19 - ResearchAndMarkets.com

Monday, April 6, 2020 - 5:32pm

ResearchAndMarkets.com identifies Over-the-counter Drugs as one of the key industries seeing increased demand due to the Coronavirus pandemic.

Key Points: 
  • ResearchAndMarkets.com identifies Over-the-counter Drugs as one of the key industries seeing increased demand due to the Coronavirus pandemic.
  • With hospitals overstretched by the crisis and mild cases of COVID-19 treatable with paracetamol and other common drugs, pharmacies and other retailers will have to keep well stocked.
  • Also, other health problems dont stop for a pandemic, and people have all the same diseases they would ordinarily have, with the same demand for pharmaceuticals.
  • Latest available reports on this sector include:

Insights on the Global Tumor Ablation Industry to 2027 - Drivers, Restraints, Opportunities & Threats - ResearchAndMarkets.com

Monday, April 6, 2020 - 5:08pm

The "Tumor Ablation - Global Market Outlook (2018-2027)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Tumor Ablation - Global Market Outlook (2018-2027)" report has been added to ResearchAndMarkets.com's offering.
  • The Global Tumor Ablation market accounted for $394.66 million in 2018 and is expected to reach $1,253.33 million by 2027 growing at a CAGR of 13.7% during the forecast period.
  • Tumor ablation is a minimally invasive image-guided technique used in the treatment of the tumors in the liver, kidney, soft tissue and bone.
  • Tumor ablation has primarily been used for the treatment of oesophagal squamous cell dysplasia, gastric antral vascular ectasia, radiation proctopathy, cholangiocarcinoma, and pancreatic neoplasia.

New Study Accurately Predicts Pregnant Woman's Risk of Spontaneous Very Preterm Birth

Monday, April 6, 2020 - 3:00pm

The study demonstrates that a ratio of maternal steroid hormones, when tested in the first trimester, accurately predicts a pregnant woman's risk for having a spontaneous preterm birth prior to 32 weeks (called "very preterm birth").

Key Points: 
  • The study demonstrates that a ratio of maternal steroid hormones, when tested in the first trimester, accurately predicts a pregnant woman's risk for having a spontaneous preterm birth prior to 32 weeks (called "very preterm birth").
  • The findings are important as early detection allows clinicians to identify those women at the greatest risk for preterm delivery and implement behavioral and clinical interventions to mitigate risk.
  • Ninety-three pregnant women who had plasma samples obtained during the late first trimester/early second trimester were included in the study.
  • Smoking, drug use, inability in maintaining a healthy weight and stress can all contribute to preterm birth risk as well.

The iTind Device Receives FDA de Novo Classification Order for Benign Prostatic Hyperplasia (BPH) Non-Surgical Treatment Device

Monday, April 6, 2020 - 2:00pm

CENTER VALLEY, Pa., April 6, 2020 /PRNewswire/ -- Olympus, a global technology leader in designing and delivering innovative solutions for medical and surgical procedures, announced today the FDA de Novo classification of the iTind device, a non-surgical device for the minimally invasive treatment of Benign Prostatic Hyperplasia (BPH).

Key Points: 
  • CENTER VALLEY, Pa., April 6, 2020 /PRNewswire/ -- Olympus, a global technology leader in designing and delivering innovative solutions for medical and surgical procedures, announced today the FDA de Novo classification of the iTind device, a non-surgical device for the minimally invasive treatment of Benign Prostatic Hyperplasia (BPH).
  • The iTind device was developed by the Israeli-based medical device manufacturer Medi-Tate.
  • Through an investment in Medi-Tate, Olympus holds the exclusive right to distribute Medi-Tate products, including the iTind device, in the U.S.
  • With the recent FDA Classification Order of the iTind device, Olympus will continue to be a global market leader in men's health.